Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | EDNRA | P25101 | 3/20 | 0.34 |
| ▸ | EDNRB | P24530 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | TSPO | P30536 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | IL1R1 | P14778 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18199797 | 0.96 | L3MBTL1 (0.49) | L3MBTL1KDM4EATMEDNRAEDNRB | |
| SCHEMBL18199804 | 0.84 | KDM4E (0.39) | L3MBTL1KDM4EATMEDNRAEDNRB | |
| SCHEMBL18622759 | 0.84 | L3MBTL1 (0.53) | L3MBTL1KDM4EATMEDNRAEDNRB | |
| SCHEMBL21578645 | 0.83 | ATM (0.38) | L3MBTL1KDM4EATMEDNRAEDNRB | |
| SCHEMBL10331692 | 0.81 | KDM4E (0.38) | L3MBTL1KDM4EATMEDNRAEDNRB | |
| SCHEMBL10331690 | 0.81 | KDM4E (0.38) | L3MBTL1KDM4EATMEDNRAEDNRB | |
| SCHEMBL18622767 | 0.81 | L3MBTL1 (0.49) | L3MBTL1KDM4EATMEDNRAEDNRB | |
| SCHEMBL14886494 | 0.80 | KDM4E (0.34) | L3MBTL1KDM4EATM | |
| SCHEMBL18199805 | 0.80 | KDM4E (0.42) | L3MBTL1KDM4EATMEDNRAEDNRB | |
| SCHEMBL14900748 | 0.79 | L3MBTL1 (0.72) | L3MBTL1KDM4EATMPTGER4TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9634260-B2 | Method for preparing conjugated compound having phenoxathiin and electron donating group of conjugated aromatic unit, and OLED device having the conjugated compound | SHENZHEN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) | 2017-04-25 | — | — | US | disclosed |
| US-9634260-B2 | Method for preparing conjugated compound having phenoxathiin and electron donating group of conjugated aromatic unit, and OLED device having the conjugated compound | SHENZHEN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) | 2017-04-25 | — | — | US | disclosed |
| US-20160322584-A1 | CONJUGATED COMPOUND HAVING PHENOXATHIINL, METHOD FOR PREPARING THE SAME AND OLED DEVICE | SHENZHEN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) | 2016-11-03 | — | — | US | disclosed |
| US-20160322584-A1 | CONJUGATED COMPOUND HAVING PHENOXATHIINL, METHOD FOR PREPARING THE SAME AND OLED DEVICE | SHENZHEN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160322584-A1 | CONJUGATED COMPOUND HAVING PHENOXATHIINL, METHOD FOR PREPARING THE SAME AND OLED DEVICE | AOC2, OCIAD2, AOX1 | L3MBTL1 3788/4885KDM4E 3510/4885ATM 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.